Notably, for subgroups that include patients <60 years old, those who have undergone more than two chemotherapy sessions, individuals without visceral and lymph node metastases, patients with a maximum of two metastatic sites, those with an ECOG score of 0, and those characterized by HER2- ER + PR + or HER2- statuses, the combined treatment approach is cost-effective. Here, ERBB2 is linked to metastatic malignant neoplasm in the lymph nodes.